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Abstract
Background: So far, many studies have investigated the distribution of CCR5 genotype between HIV-1 infected patients and
uninfected people. However, no definite results have been put forward about whether heterozygosity for a 32-basepair
deletion in CCR5 gene (CCR5-D32) can affect HIV-1 susceptibility.
Methods: We performed a meta-analysis of 18 studies including more than 12000 subjects for whom the CCR5-D32
polymorphism was genotyped. Odds ratio (OR) with 95% confidence interval (CI) were employed to assess the association
of CCR5-D32 polymorphism with HIV-1 susceptibility.
Results: Compared with the wild-type CCR5 homozygotes, the pooled OR for CCR5-D32 heterozygotes was 1.02 (95%CI,
0.88–1.19) for healthy controls (HC) and 0.95 (95%CI, 0.71–1.26) for exposed uninfected (EU) controls. Similar results were
found in stratified analysis by ethnicity, sample size and method of CCR5-D32 genotyping.
Conclusions: The meta-analysis indicated that HIV-1 susceptibility is not significantly affected by heterozygosity for CCR5-
D32.
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Introduction
Inter-individual variability in susceptibility to HIV-1 infection,
transmission, disease progression, and response to antiviral
therapy has been attributed to host variability in multiple genes
[1]. CC chemokine receptor 5 (CCR5) and CXC chemokine
receptor 4 (CXCR4) are co-receptors for the entry of human
immunodeficiency virus type 1 (HIV-1) into target cells [2]. A
natural knockout deletion of 32 bases in CCR5 gene introduces a
premature stop codon resulting in truncated protein product [3].
People homozygous for CCR5-D32 are naturally resistant to R5
HIV infection and the heterozygous state is associated with up to
2–4 years delay in disease progression [4]
,. Recently, Allers et al
reported that they have successfully cured a HIV infected patient
through CCR5-D32/D32 stem cell transplantation [5,6]. On the
other hand, the evidence for protection from HIV-1 infection
among CCR5-D32 heterozygotes is mixed. A meta-analysis of
Despina et al suggested that perinatal infection rates are not
strongly determined by the number of functional CCR5
receptors in the children [7]. For adults, some studies have
reported that CCR5-D32 heterozygotes could be protective
against HIV transmission [8–15], whereas others have not
confirmed that [16–28]. Therefore, we performed a meta-
analysis of the accumulated data to address this question
definitively.
Materials and Methods
Search Strategy and Study Selection
English database of Google Scholar (GS), PubMed and Chinese
database of CNKI were searched till June 2011 using key words:
CCR5-D32 and HIV-1. Studies satisfying the following criteria
were included: case-control studies reporting the association of
CCR5-D32 genotype with HIV-1 susceptibility, distribution of
CCR5-D32 genotype between the cohorts was shown, not a
prenatal HIV-1 infection study.
Data Extraction and Statistical Analysis
Two reviewers( SiJie Liu, Jie Wu) independently performed data
extraction and then checked the results together. The following
information was extracted from included studies: authors, year of
publication, ethnicity, country, sample size, method of CCR5-D32
genotyping and CCR5-D32 genotype of cohorts.
Odds ratio (OR) and its 95% confidence intervals (CI) were
used to evaluate the association of CCR5-D32 heterozygotes with
HIV-1 susceptibility. Subgroups were identified by ethnicity,
sample size and method of CCR5-D32 genotyping. A chi-square-
based Q-test was carried out to assess heterogeneity across studies
[29]. A P value less than 0.10 was used to denote statistical
significance. Fixed effects (Mantel and Haenszel) model was
employed to pool the effects of studies without heterogeneity,
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used [30,31]. Publication bias was evaluated by Egger’s and Begg’s
test with funnel plots [32,33]. Asymmetry of the funnel plot
suggests publication bias. A P value less than 0.05 was used to
denote statistical significance. One-way sensitivity analyses were
performed to examine the influence of individual studies on meta-
analysis’s results. Data were analyzed using Stata version 10.0
(StataCorp, College Station, Tex).
Results
Figure 1 summarized the selection process of literatures. The
electronic search yielded 1232 records, after screening over titles
and/or abstracts, 24 articles were selected for further review.
Finally, 18 studies involving 6427 cases and 5809 controls were
included in the meta-analysis. Study sample size ranged from 140
to 2605 subjects. Study characteristics of the 18 eligible studies
were summarized in Table 1. Distribution of CCR5 genotype
among subjects was shown in Table 2. Briefly, 9 studies involved
Caucasian subjects [8,10–12,17,22–24], 4 studies involved Mon-
goloid subjects [16,21,25,28], 3 studies involved African subjects
[8,12,24], 3 studies involved Latina subjects [12,18,27]. In
addition to CCR5-D32 genotype, 8 studies provided the subjects’
CCR2-64I genotype [10,16,19–21,26–28], 5 studies provided the
subjects’ SDF-1 genotype [16,20,21,26,27]. All studies were done
in subjects of mixed genders except that by Downer et al [24],
which only included women.
Compared with the wild-type CCR5 homozygotes, the pooled
OR for CCR5-D32 heterozygotes was 1.02 (95%CI, 0.88–1.19,
p=0.073) for healthy controls (HC) (figure 2a) and 0.95 (95%CI,
0.71–1.26, p=0.182) for exposed uninfected (EU) controls
(figure 2b). There was no significant between-study heterogeneity.
No asymmetry is observed in the funnel plots (figure 3a, 3b).
We also performed stratified analysis by ethnicity, sample size
and method of CCR5-D32 genotyping. The results were
summarized in Table 3. All the results were consisted with overall
analysis and no publication bias were observed.
Sensitive analysis was conducted by deleting one study at a time
to examine the influence of individual data-set to the pooled ORs.
All of the corresponding pooled ORs were not materially altered
(Data not shown).
Discussion
Meta-analysis offers a powerful method to synthesize informa-
tion of independent studies with similar intention. It has been
proved that CCR5-D32 homozygotes are associated with near
complete protection to HIV-1 infection. Moreover, published data
have demonstrated that a disease-retarding effect of CCR5-D32
heterozygosity in HIV-1 infected individuals [34]. Whereas it
Figure 1. Selection process of studies included in the meta-analysis.
doi:10.1371/journal.pone.0035020.g001
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Study (year) Country Genotyping method Ethnicity Sample size (case/control)
Battiloro (2000) [17] Italy PCR Caucasian 256/806
Deng (2004) [28] China PCR Mongoloid 88/119
Diaz (2000) [18] Colombia PCR Latina 29/188
Downer (2002) [24] USA PCR-RFLP Mixed 929/445
Grimaldi(2002)[13] Brazil PCR Mixed 113/549
Li (2003) [26] China PCR Mongoloid 94/46
Liu (2004) [20] USA PCR Mixed 316/513
Lockett (1999) [19] Britain PCR Mixed 86/105
Oh(2008)[8] German PCR Caucasian 610/427
African 35/26
Papa (2000) [10] Greece PCR Caucasian 138/239
Paz-y-Mino (2005) [27] Ecuador PCR Latina 295/50
Philpott (2003) [12] USA PCR-RFLP Mixed 2047/558
Takacova (2008) [22] Slovakia PCR Caucasian 162/198
Tan (2010) [16] China PCR Mongoloid 250/237
Tang (2010) [25] China PCR-LDR Mongoloid 245/223
Trecarichi(2006)[11] Italy PCR Caucasian 120/120
Veloso(2010)[23] Span PCR Caucasian 184/236
Wang (2003) [21] China PCR Mongoloid 330/474
doi:10.1371/journal.pone.0035020.t001
Table 2. Distribution of CCR5 genotype of included studies.
Study Ethnicity HIV-infected Healthy Controls Exposed but uninfected
+/+
1 +/g
2 +/+ +/g +/+ +/g
Battiloro Caucasian 232 24 744 62
Deng Mongoloid 88 0 117 2
Diaz Latina 28 1 142 8 37 1
Downer Mixed 879 50 422 23
Grimaldi Mixed 103 10 520 29
Li Mongoloid 90 4 45 1
Liu Mixed 261 55 354 68 69 22
Lockett Mixed 63 23 38 10 40 17
Oh Caucasian 595 115 352 75
African 35 0 25 1
Papa Caucasian 132 6 216 23
Paz-y-Mino Latina 292 3 50 0
Philpott Mixed 1940 107 513 45
Takacova Caucasian 137 25 164 34
Tan Mongoloid 226 24 222 15
Tang Mongoloid 221 24 209 14
Trecarichi Caucasian 111 9 24 6
Veloso Caucasian 144 40 174 26 31 5
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35020Figure 2. Odds ratio of HIV-1 infection of CCR5-D32 heterozygotes versus wild type CCR5 homozygotes. The area of the black square
reflects the weight of each study. The diamonds represent the combined odds ratio and 95% confidence interval using the fixed effects model for (a)
healthy controls (HC) and (b) exposed uninfected controls (EU).
doi:10.1371/journal.pone.0035020.g002
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HIV-1 susceptibility. Thus we performed this meta-analysis
involving 18 eligible studies with 6427 patients and 5809 controls.
The study demonstrated that CCR5-D32 heterozygosity has little
or no protective effect against HIV-1 infection among adults. This
result is similar to a previous study of perinatal HIV-1 infection
[7]. Several factors might underlie the lack of observed association
between CCR5-D32 heterozygosity and HIV-1 susceptibility.
First, the expression of CCR5 is influenced by factors other than
CCR5 genotype. Even an individual with CCR5-D32 heterozy-
gosity could still express high level of CCR5 [35,36]. Second,
susceptibility to HIV-1 infection is affected by a combination of
genes besides CCR5. The CCR5-D32 heterozygotes couldn’t
provide a full resistant to HIV-1 infection as the homozygotes. It is
possible that a single D32 allele exerts a protective effect against
HIV-1 infection only if it occurs combined with other protective
factors [9].
There are a number of limitations to our study. First, although
test of publication bias have generated negative results, studies
solely in conference or in local journals may have been overlooked.
Second, HIV-1 of X4 strain take advantage of CXCR4 as co-
receptor. It has been reported that new infections in individuals
are primarily established by strains that use R5 [37–39].
Currently, it is remains controversial about if HIV could use
CXCR4 as co-receptor in primary HIV infection [40]. Primary
infection with CXCR4-using HIV-1 strains is believed to be a rare
event [41]. Thus, we might believe that in most of the cases HIV-1
R5 strain cause the initial infection, rather than the X4 strain.
Although we couldn’t exclude the interference of X4 viruses, it is
unlikely that virus of X4 strain would significantly affect the
results. Third, controls of some studies were solely derived from
healthy individuals. For studies concerning disease susceptibility,
it’ll be more proper to take samples from exposed uninfected
people as controls. Fourth, susceptibility to HIV-1 is influenced by
multiple factors other than CCR5, they might interfere the
precision of analysis.
In conclusion, our study involving more than 12000 subjects
suggested that CCR5-D32 heterozygosity has little effect on
protecting from HIV-1 infection. Therefore, other chemokine
receptors and transmission mechanisms may play a more
important role.
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Figure 3. Funnel plots to detect publication bias in the meta-analysis. (a) Healthy controls considered; (b) exposed uninfected controls
considered. The horizontal line indicates the pooled log odds ratio (OR) and guidelines to assist in visualizing the funnel are pooled at 95% pseudo
confidence limits for this estimate.
doi:10.1371/journal.pone.0035020.g003
Table 3. Stratified analysis of CCR5-D32 heterozygotes and
susceptibility to HIV-1.
Variable Healthy Controls Exposed but uninfected
OR (95%CI) P
1 OR (95%CI) P
Ethnicity
African 1.17 (0.71–1.93) 0.604
Caucasian 1.06 (0.73–1.53) 0.005 1.31 (0.25–6.85) 0.029
Latina 1.28 (0.62–2.61) 0.942
Mongoloid 0.63 (0.39–1.01) 0.995
Genotyping Method
PCR 0.94 (0.79–1.12) 0.239 1.04 (0.76–1.44) 0.233
PCR-RFLP 1.32 (0.99–1.78) 0.110
Sample Size
.800 1.09 (0.91–1.30) 0.152
,800 0.87 (0.65–1.16) 0.144 0.81 (0.57–1.14) 0.233
1P value of Q-test for heterogeneity test.
doi:10.1371/journal.pone.0035020.t003
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